文献速递炎症性肠病

基于血清蛋白水平监测克罗恩病内镜活动的检测方法开发与验证

Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins.
PubMed 文献 · Gastroenterology · 2019-11-08

该研究开发了一种基于13种血清蛋白的內镜愈合指数(EHI),用于识别克罗恩病(CD)患者的内镜缓解。在278例训练队列中开发,并在两个独立验证队列(116例早期生物制剂初治和195例慢性生物制剂暴露患者)中验证。EHI在验证队列1中AUROC为0.962,队列2为0.693,与粪便钙卫蛋白相当,优于血清CRP。

要点

  • EHI基于13种血清蛋白,用于无创评估CD内镜活动。
  • EHI识别内镜缓解的AUROC在早期CD中达0.962,慢性CD中0.693。
  • EHI准确性优于血清CRP,与粪便钙卫蛋白相当。

核心结论

  • EHI是一种基于13种血清蛋白的指数,可识别CD患者的内镜缓解,总体准确性良好但两个队列间存在差异。
  • EHI的AUROC值与粪便钙卫蛋白相当,高于血清CRP。

研究设计与样本

  • 研究基于278例来自跨国训练队列的CD患者样本开发了EHI检测。
  • 使用两个独立CD患者队列验证:116例生物制剂初治早期CD患者(验证队列1)和195例生物制剂暴露慢性CD患者(验证队列2)。
  • 通过AUROC分析评估EHI识别活动性疾病与缓解(SES-CD≤2且各段≤1,或CDEIS<3)的能力。

主要发现

  • EHI评分范围0-100,评分越高表示内镜下的CD活动越严重。
  • 验证队列1中EHI识别缓解的AUROC为0.962(95%CI 0.942-0.982),验证队列2中为0.693(95%CI 0.619-0.767)。
  • cutoff值20分识别缓解的敏感性最高:验证队列1为97.1%,验证队列2为83.2%,特异性分别为69.0%和36.6%。
  • cutoff值50分识别缓解的特异性最高:验证队列1为100%,验证队列2为87.8%,敏感性分别为37.3%和30.0%。

关键数值与推荐

  • 内镜缓解定义为SES-CD≤2且各段≤1,或CDEIS<3。
  • EHI评分范围0-100,评分越高表示内镜活动越重。
  • cutoff 20分:验证队列1敏感性97.1%、特异性69.0%;验证队列2敏感性83.2%、特异性36.6%。
  • cutoff 50分:验证队列1特异性100%、敏感性37.3%;验证队列2特异性87.8%、敏感性30.0%。

临床怎么用

  • EHI可能用于临床实践中评估CD患者的内镜活动。
  • EHI可作为无创工具识别内镜缓解,尤其适用于早期CD患者。
  • EHI准确性优于血清CRP,与粪便钙卫蛋白相当,可考虑作为替代或补充监测手段。

局限性

  • EHI在两个验证队列中的准确性存在差异,慢性生物制剂暴露患者中AUROC较低。
  • 研究未报告EHI在临床决策中的实际影响或成本效益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Noninvasive tests to measure endoscopic activity in patients with Crohn's disease (CD) have limitations. We aimed to develop a test to identify patients in remission, based on endoscopic analysis, and monitor CD activity based on serum levels of proteins. METHODS: We developed a test to measure 13 proteins in blood (ANG1, ANG2, CRP, SAA1, IL7, EMMPRIN, MMP1, MMP2, MMP3, MMP9, TGFA, CEACAM1, and VCAM1), called the endoscopic healing index [EHI], using samples from 278 patients with CD from a multinational training cohort. We validated the test using 2 independent cohorts of patients with CD: 116 biologic-naive patients with early-stage CD (validation cohort 1) and 195 biologic-exposed patients with chronic CD (validation cohort 2). The ability of the test to identify patients with active disease vs patients in remission (defined as a simple endoscopic score for CD of ≤2 and ≤1 in each segment, or a total CD endoscopic index of severity score <3) was assessed by using area under receiver operating characteristic curve (AUROC) analysis. The diagnostic accuracy of the test was compared with that of measurement of serum C-reactive protein (CRP) and fecal calprotectin. RESULTS: The EHI scores range from 0 to 100 units; higher scores indicate more severe CD activity, based on endoscopy findings. The EHI identified patients in remission with an AUROC of 0.962 in validation cohort 1 (95% confidence interval, 0.942-0.982) and an AUROC of 0.693 in validation cohort 2 (95% confidence interval, 0.619-0.767), regardless of CD location or phenotype. A cutoff value of 20 points identified patients in remission with the highest level of sensitivity (97.1% in validation cohort 1 and 83.2% in validation cohort 2), with specificity values of 69.0% and 36.6%, respectively. A cutoff value of 50 points identified patients in remission with the highest level of specificity (100% in validation cohort 1 and 87.8% in validation cohort 2), with sensitivity values of 37.3% and 30.0%, respectively. The EHI identified patients in remission with a significantly higher AUROC value than the test for CRP (0.876, P < .001 in validation cohort 1 and 0.624, P = .109 in validation cohort 2). In analysis of patients with available FC measurements, the AUROC value for the EHI did not differ significantly from that of measurement of FC (AUROC, 0.950 for EHI vs AUROC, 0.923 for FC; P = .147 in validation cohort 1 and AUROC, 0.803 for EHI vs AUROC, 0.854 for FC; P = .298 in validation cohort 2). CONCLUSIONS: We developed an index called the EHI to identify patients with CD in endoscopic remission based on blood levels of 13 proteins. The EHI identified patients with resolution of endoscopic disease activity, with good overall accuracy, although with variation between the 2 cohorts assessed. The EHI AUROC values were comparable to measurement of FC and higher than measurement of serum CRP. The test might be used in practice to assess endoscopic activity in patients with CD.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. D'Haens G, Kelly O, Battat R, et al. Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins. Gastroenterology. 2019. PMID: 31711925. doi:10.1053/j.gastro.2019.10.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。